Attila Pálinkás

Dr. Attila Pálinkás

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2002 in JACC
Verified
Journal Article
Closed access
EAEmanuele Antonielli
Emanuele Antonielli
APAlfredo Pizzuti
Alfredo Pizzuti
APAttila Pálinkás
Attila Pálinkás
MTMattia Tanga
Mattia Tanga
NGN.OÈmi Gruber
N.OÈmi Gruber
EPEugenio Picano
Eugenio Picano

1 July 2001 in Journal Of Hypertension
Verified
Journal Article
Closed access
EPEugenio Picano
Eugenio Picano
APAttila Pálinkás
Attila Pálinkás
RARobert Amyot
Robert Amyot
Arterial hypertension can provoke a reduction in coronary flow reserve through several mechanisms that are not mutually exclusive (i.e. epicardial coronary artery disease (CAD), left ventricular hypertrophy and structural and/or functional microvascular disease). These different targets of arterial hypertension should be explored with different diagnostic markers. In fact, stress-induced wall motion abnormalities are highly specific for angiographically assessed epicardial CAD, whereas ST segment depression and/or myocardial perfusion abnormalities are frequently found with angiographically normal coronary arteries associated with left ventricular hypertrophy and/or microvascular disease. Exercise-electrocardiography stress test can be used to screen patients with negative maximal test due to its excellent negative predictive value, which is high and comparable in normotensives and hypertensives. When exercise-electrocardiography stress test is positive (or uninterpretable or ambiguous), an imaging stress-echo test is warranted for a reliable identification of significant, prognostically malignant epicardial CAD in view of an ischemia-guided revascularization.

18 January 2017 in Cardiovascular Ultrasound
Verified
Journal Article
Open access
PDF file
EPEugenio Picano
Eugenio Picano
QCQuirino Ciampi
Quirino Ciampi
Rodolfo CitroRodolfo Citro
Rodolfo Citro
Antonello D'AndreaAntonello D'Andrea
Antonello D'Andrea
MSMaria Chiara Scali
Maria Chiara Scali
PCPaolo Colonna
Paolo Colonna
Stress echocardiography (SE) has an established role in evidence-based guidelines, but recently its breadth and variety of applications have extended well beyond coronary artery disease (CAD). We lack a prospective research study of SE applications, in and beyond CAD, also considering a variety of signs in addition to regional wall motion abnormalities. In a prospective, multicenter, international, observational study design, > 100 certified high-volume SE labs (initially from Italy, Brazil, Hungary, and Serbia) will be networked with an organized system of clinical, laboratory and imaging data collection at the time of physical or pharmacological SE, with structured follow-up information. The study is endorsed by the Italian Society of Cardiovascular Echography and organized in 10 subprojects focusing on: contractile reserve for prediction of cardiac resynchronization or medical therapy response; stress B-lines in heart failure; hypertrophic cardiomyopathy; heart failure with preserved ejection fraction; mitral regurgitation after either transcatheter or surgical aortic valve replacement; outdoor SE in extreme physiology; right ventricular contractile reserve in repaired Tetralogy of Fallot; suspected or initial pulmonary arterial hypertension; coronary flow velocity, left ventricular elastance reserve and B-lines in known or suspected CAD; identification of subclinical familial disease in genotype-positive, phenotype- negative healthy relatives of inherited disease (such as hypertrophic cardiomyopathy). We expect to recruit about 10,000 patients over a 5-year period (2016-2020), with sample sizes ranging from 5,000 for coronary flow velocity/ left ventricular elastance/ B-lines in CAD to around 250 for hypertrophic cardiomyopathy or repaired Tetralogy of Fallot. This data-base will allow to investigate technical questions such as feasibility and reproducibility of various SE parameters and to assess their prognostic value in different clinical scenarios. The study will create the cultural, informatic and scientific infrastructure connecting high-volume, accredited SE labs, sharing common criteria of indication, execution, reporting and image storage of SE to obtain original safety, feasibility, and outcome data in evidence-poor diagnostic fields, also outside the established core application of SE in CAD based on regional wall motion abnormalities. The study will standardize procedures, validate emerging signs, and integrate the new information with established knowledge, helping to build a next-generation SE lab without inner walls.

1 December 2001 in The American Journal of Cardiology
Verified
Journal Article
Closed access
LPLorenza Pratali
Lorenza Pratali
EPEugenio Picano
Eugenio Picano
POPetar Otasevic
Petar Otasevic
CVCarlo Vigna
Carlo Vigna
APAttila Pálinkás
Attila Pálinkás
PLPatrizia Landi
Patrizia Landi

17 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EPEugenio Picano
Eugenio Picano
QCQuirino Ciampi
Quirino Ciampi
LCLauro Cortigiani
Lauro Cortigiani
AAAdelaide M. Arruda-Olson
Adelaide M. Arruda-Olson
Clarissa Borguezan DarosClarissa Borguezan Daros
Clarissa Borguezan Daros
T(The Stress Echo 2030 Study Group of the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI)
The Stress Echo 2030 Study Group of the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI)
With stress echo (SE) 2020 study, a new standard of practice in stress imaging was developed and disseminated: the ABCDE protocol for functional testing within and beyond CAD. ABCDE protocol was the fruit of SE 2020, and is the seed of SE 2030, which is articulated in 12 projects: 1-SE in coronary artery disease (SECAD); 2-SE in diastolic heart failure (SEDIA); 3-SE in hypertrophic cardiomyopathy (SEHCA); 4-SE post-chest radiotherapy and chemotherapy (SERA); 5-Artificial intelligence SE evaluation (AI-SEE); 6-Environmental stress echocardiography and air pollution (ESTER); 7-SE in repaired Tetralogy of Fallot (SETOF); 8-SE in post-COVID-19 (SECOV); 9: Recovery by stress echo of conventionally unfit donor good hearts (RESURGE); 10-SE for mitral ischemic regurgitation (SEMIR); 11-SE in valvular heart disease (SEVA); 12-SE for coronary vasospasm (SESPASM). The study aims to recruit in the next 5 years (2021–2025) ≥10,000 patients followed for ≥5 years (up to 2030) from ≥20 quality-controlled laboratories from ≥10 countries. In this COVID-19 era of sustainable health care delivery, SE2030 will provide the evidence to finally recommend SE as the optimal and versatile imaging modality for functional testing anywhere, any time, and in any patient.

13 July 2005 in European Heart Journal
Verified
Journal Article
Open access
PDF file
RSRosa Sicari
Rosa Sicari
APAttila Pálinkás
Attila Pálinkás
EPEmilio G. Pasanisi
Emilio G. Pasanisi
LVLucia Venneri
Lucia Venneri
EPEugenio Picano
Eugenio Picano
Aims Patients with normal coronary arteries have a heterogeneous prognosis. Aim of this study was to assess whether dipyridamole stress echocardiography positivity identifies a prognostically less benign subset. Methods and results We selected 457 patients (245 males; 56±10 years) who underwent stress high-dose dipyridamole echocardiography and had angiographically non-significant (<50% visually assessed) stenosis in any major vessel and preserved left ventricular function. All patients were followed up for a median of 7.1 years (first quartile 5 and third quartile 10.5). Dipyridamole echocardiography test (DET) positivity for regional dysfunction occurred in 43(9%) patients. Kaplan–Meier survival estimates showed a significant better outcome for those patients with negative dipyridamole echocardiography test compared with those with a positive test (90 vs. 75.7%, at 140 months of follow-up, P=0.0018). At multivariable analysis, mild or moderate irregularity on coronary arteriogram (HR=3.3, CI 95%=1.7–6.2), diabetes (HR=3.5, CI 95%=1.4–9.2), and wall motion score index at peak stress (HR=6.7, CI 95%=2.5–17.8) were independent predictors of all-cause death. Conclusion DET adds incremental value to the prognostic stratification achieved with clinical and angiographic data in the subset of patients with normal or near-normal coronary arteries.